Biotricity (Nasdaq:BTCY) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

BTCY 주식 개요

는 미국에서 생체 인식 데이터 모니터링 솔루션을 제공하는 의료 기술 회사입니다.

BTCY 기본 분석
눈송이 점수
가치 평가	1/6
미래 성장	1/6
과거 실적	0/6
재무 상태	2/6
배당금	0/6

보상

수익은 연간 17.3% 증가할 것으로 예상됩니다.

위험 분석

지난 5년간 매년 수익이 17.6% 씩 감소했습니다.

마이너스 주주 지분

지난 1년 동안 주주가 크게 희석되었습니다.

의미 있는 시가총액이 없습니다. ( $19M )

+ 1 더 많은 위험

Biotricity, Inc. 경쟁사

Augmedix

NasdaqCM:AUGX

US$41.2m

Streamline Health Solutions

NasdaqCM:STRM

US$30.4m

iCoreConnect

NasdaqCM:ICCT

US$8.8m

NantHealth

OTCPK:NHIQ

US$19.6m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Biotricity
과거 주가
현재 주가	US$0.87
52주 최고치	US$4.06
52주 최저치	US$0.70
베타	1.41
11개월 변경	-26.89%
3개월 변경 사항	-41.22%
1년 변경 사항	-74.56%
33년 변화	-95.39%
5년 변화	-79.29%
IPO 이후 변화	-94.53%

최근 뉴스 및 업데이트

Recent updates

주주 수익률

	BTCY	US Healthcare Services	US 마켓
7D	-7.2%	1.9%	-0.2%
1Y	-74.6%	-19.5%	22.9%

수익률 대 산업: BTCY 지난 1년 동안 -21.4 %를 반환한 US Healthcare Services 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: BTCY 지난 1년 동안 23.3 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is BTCY's price volatile compared to industry and market?
BTCY volatility
BTCY Average Weekly Movement	13.0%
Healthcare Services Industry Average Movement	8.9%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.3%
10% least volatile stocks in US Market	2.9%

안정적인 주가: BTCY 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: BTCY 의 주간 변동성( 13% )은 지난 1년 동안 안정적이었지만 여전히 US 의 75%보다 높습니다. 주식.

회사 소개

설립	직원	CEO	웹사이트
n/a	55	Waqaas Al-Siddiq	www.biotricity.com

는 미국에서 생체 인식 데이터 모니터링 솔루션을 제공하는 의료 기술 회사입니다. 이 회사는 라이프스타일 및 만성 질환에 대한 진단 및 사후 진단 솔루션을 포함하여 의료, 헬스케어 및 소비자 시장에 원격 모니터링 솔루션을 제공하는 데 주력하고 있습니다. 통합 심전도 장치인 Bioflux 모바일 심장 원격 측정 솔루션과 환자의 심전도 모니터링 데이터를 분석 및 종합하는 심전도 분석 소프트웨어 및 소프트웨어 구성 요소를 제공합니다.

Biotricity, Inc. 기본 사항 요약

Biotricity 의 수익과 매출은 시가총액과 어떻게 비교하나요?
BTCY 기본 통계
시가총액	US$19.09m
수익(TTM)	-US$15.39m
수익(TTM)	US$11.63m

1.6x

P/S 비율

-1.2x

P/E 비율

BTCY 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
BTCY 손익 계산서(TTM)
수익	US$11.63m
수익 비용	US$4.01m
총 이익	US$7.62m
기타 비용	US$23.00m
수익	-US$15.39m

최근 보고된 수익

Dec 31, 2023

다음 수익 날짜

n/a

주당 순이익(EPS)	-0.72
총 마진	65.52%
순이익 마진	-132.33%
부채/자본 비율	-82.6%

BTCY 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

BTCY 주식 개요

보상

위험 분석

Biotricity, Inc. 경쟁사

NasdaqCM:AUGX

US$41.2m

NasdaqCM:STRM

US$30.4m

NasdaqCM:ICCT

US$8.8m

OTCPK:NHIQ

US$19.6m

가격 내역 및 성능

최근 뉴스 및 업데이트

Biotricity, Inc. Launches Direct-To-Consumer Heart Health Screening Service, Heartsecure, Making Heart Health Services

Biotricity, Inc. has filed a Follow-on Equity Offering in the amount of $2.684644 million.

Biotricity Inc. Announces High Demand for Its Latest Device, Biotres Pro

Biotricity, Inc. has withdrawn its Follow-on Equity Offering in the amount of $10.55 million.

Nasdaq Notifies Biotricity That the Nasdaq Hearings Panel Grants Its Request to Continue Its Listing on Nasdaq

Biotricity, Inc. announced that it has received $2 million in funding

Recent updates

Biotricity, Inc. Launches Direct-To-Consumer Heart Health Screening Service, Heartsecure, Making Heart Health Services

Biotricity, Inc. has filed a Follow-on Equity Offering in the amount of $2.684644 million.

Biotricity Inc. Announces High Demand for Its Latest Device, Biotres Pro

Biotricity, Inc. has withdrawn its Follow-on Equity Offering in the amount of $10.55 million.

Nasdaq Notifies Biotricity That the Nasdaq Hearings Panel Grants Its Request to Continue Its Listing on Nasdaq

Biotricity, Inc. announced that it has received $2 million in funding

Biotricity Announces Strategic Partnership for Cardiac Screenings in Patients with Co-Morbidities

Biotricity, Inc. announced a financing transaction

Biotricity Unveils That Improved Margins Resulted from Latest Advancements to Its Proprietary Cardiac Ai Cloud Platform and Announces Plans for Continued Expansion of Its Cardiac AI Cloud

Biotricity, Inc. has filed a Follow-on Equity Offering in the amount of $10.55 million.

Biotricity, Inc. has filed a Follow-on Equity Offering in the amount of $10.55 million.

Biotricity, Inc. announced delayed 10-Q filing

Biotricity, Inc. Receives A Delisting Determination Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Investors Give Biotricity, Inc. (NASDAQ:BTCY) Shares A 38% Hiding

Biotricity Inc. Expands Development of its Cardiac AI Cloud Platform with Data Ecosystem of over 360 Billion Heartbeats

New major risk - Share price stability

Second quarter 2024 earnings released: US$0.44 loss per share (vs US$0.57 loss in 2Q 2023)

Biotricity, Inc. to Report Q2, 2024 Results on Nov 14, 2023

Biotricity Releases Another Groundbreaking Product: Biotres Pro

New major risk - Market cap size

Many Still Looking Away From Biotricity, Inc. (NASDAQ:BTCY)

Biotricity Continues to Expand Patent Portfolio with Latest Patent Filing for Bioheart Device

Biotricity, Inc. Announces Patent Filing for Cutting-Edge Biotres Device

Biotricity, Inc. has completed a Follow-on Equity Offering.

New major risk - Financial position

First quarter 2024 earnings released: US$0.069 loss per share (vs US$0.59 loss in 1Q 2023)

Biotricity Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with the Market Value of Listed Securities Requirement

Biotricity Inc. Expands Its Proprietary AI Model and Deepens Relationship with Amazon Aws and Google's Tensor Flow for Remote Cardiac Care Applications

Biotricity Regains Nasdaq Listing Compliance

Biotricity, Inc. Provides Earnings Guidance for the First Fiscal Quarter Ended June 30, 2023

Full year 2023 earnings released: US$0.38 loss per share (vs US$0.67 loss in FY 2022)

Third quarter 2023 earnings: Revenues exceed analyst expectations

Biotricity Receives A Letter from Nasdaq Capital Market Regarding Minimum Bid Price

Consensus revenue estimates fall by 19%

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$3.83

Less than half of directors are independent

Biotricity, Inc. Launches Cardiac Disease Management Solution Following 2 Successful Pilots with Oklahoma & Kentucky Clinics

Less than half of directors are independent

Biotricity GAAP EPS of -$0.09, revenue of $2.06M

Biotricity Announces Management Changes

Biotricity, Inc.: A First Take

Biotricity, Inc. announced delayed annual 10-K filing

Is Biotricity (NASDAQ:BTCY) Using Debt In A Risky Way?

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Biotricity, Inc. to Report Q3, 2022 Results on Feb 14, 2022

High number of new directors

Does Biotricity (NASDAQ:BTCY) Have A Healthy Balance Sheet?

High number of new directors

Biotricity: Capital Raise Leads To Buying Opportunity

Biotricity Common Stock Deleted from Other OTC

Biotricity, Inc. announced delayed 10-Q filing

Biotricity, Inc. Announces Earnings Guidance for the Fiscal 2022

Biotricity, Inc. to Report Q3, 2021 Results on Feb 11, 2021

Biotricity, Inc. announced that it has received $9.5575 million in funding

Biotricity Announces New Solution for Personal Heart Management with Bioheart

Biotricity, Inc. Prepares 510(k) FDA Filing for Biotres

Biotricity Inc. Announces Launch of Its Bioflux® Direct Program

Biotricity, Inc. announced a financing transaction